Gilead to purchase cancer cells drugmaker Immunomedics for $21 billion

(Reuters) – Gilead Sciences Inc will certainly obtain biopharmaceutical business Immunomedics Inc for $21 billion, a relocation that will certainly reinforce its cancer cells profile by acquiring acce …
Read More